Why the study?
Does bedside testing for H-FABP improve risk stratification for adverse outcomes in non-high-risk patients with acute PE?
Does bedside testing for H-FABP improve risk stratification for adverse outcomes in non-high-risk patients with acute PE?
Bedside H-FABP testing, especially when integrated into a novel score, is useful for rapid risk stratification of non-high-risk acute pulmonary embolism without needing echocardiography.
Answers are grounded in this paper and cite their sources.
May aid rapid PE risk stratification without echo; leaves open prospective validation before practice change.
Bedside testing for H-FABP appears a useful tool for immediate risk stratification of non-high-risk patients with acute PE, who may be at increased risk of an adverse outcome, in particular if integrated in a novel score without the need of echocardiographic examination.
No takes yet. Share an insight, caveat, or question.
Lankeit et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: